Oramed Pharmaceuticals (Seite 1412)
eröffnet am 28.03.07 10:26:47 von
neuester Beitrag 12.06.24 15:05:28 von
neuester Beitrag 12.06.24 15:05:28 von
Beiträge: 19.671
ID: 1.121.564
ID: 1.121.564
Aufrufe heute: 21
Gesamt: 1.543.345
Gesamt: 1.543.345
Aktive User: 0
ISIN: US68403P2039 · WKN: A1CTNU · Symbol: OJU1
2,1400
EUR
+1,57 %
+0,0330 EUR
Letzter Kurs 14:02:38 Tradegate
Neuigkeiten
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,5800 | +26,09 | |
| 8,3500 | +24,63 | |
| 30,00 | +23,97 | |
| 17,380 | +17,75 | |
| 323,60 | +17,59 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 10,490 | -13,16 | |
| 7,1900 | -20,02 | |
| 0,9500 | -22,76 | |
| 5,01 | -22,92 | |
| 80,22 | -23,42 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 46.090.966 von kwhistler am 20.12.13 15:47:03wow 
was für ein Volumen!
ist ja fast schon wie bei der Telekom
was für ein Volumen!
ist ja fast schon wie bei der Telekom
Antwort auf Beitrag Nr.: 46.090.916 von kwhistler am 20.12.13 15:43:04Hier die News 
Oramed Announces Successful Results from Ex-US Pharmacokinetic Study of its Oral Insulin for the Treatment of Type 1 Diabetes
Company Additionally Anticipates Results from Phase 2a FDA Study for Type 2 Diabetes in January
JERUSALEM December 20, 2013-Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today successful results in a clinical trial testing the pharmacokinetic dose response of its oral insulin capsule (ORMD-0801) in type 1 diabetes patients.
Patients were treated with a different dose of oral insulin at each study visit; blood glucose and insulin levels were then monitored for the ensuing five hours. Patient responses positively correlated with administered doses, as did the duration of the effect.
"Based on these and the notable results from our previous oral insulin trials in type 1 diabetes, we continue to move forward with this indication in parallel to our advanced clinical studies in type 2 diabetes," commented CEO Nadav Kidron.
Type 1 diabetes (T1DM) is an autoimmune disease wherein the body destroys its own insulin-producing cells, leaving patients completely dependent on external insulin sources. The disease, formerly known as juvenile diabetes, currently affects both young and adult populations. According to the International Diabetes Federation, T1DM is on the rise at a rate of 3% per year and currently affects approximately 36 million people worldwide - about 10% of the global diabetes population.
About ORMD-0801 Oral Insulin and T1DM
T1DM is currently treated with two types of insulin replacement therapies: long-acting insulin (basal) to help maintain stable insulin levels during fasting periods, and pre-meal insulin (bolus) doses. Oramed proposes to introduce ORMD-0801 to replace the mealtime (bolus) insulin doses, which would significantly reduce the number of daily injections. Additionally, oral administration offers the benefit of reduced systemic exposure and may enable tighter regulation of blood sugar levels by directly affecting glucose control in the liver. For more information on ORMD-0801, the content of which is not part of this press release, please visit http://oramed.com/index.php?page=14
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (POD) technology is based on over 30 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently in Phase 2 clinical trials on patients with type 2 diabetes (T2DM) under an Investigational New Drug application with the U.S. Food and Drug Administration, and with its oral exenatide capsule (ORMD-0901; a GLP-1 analog), which has been assessed in healthy volunteers (Phase 1b) and is currently being tested in T2DM patients (Phase 2a). Oramed is also moving forward with clinical trials of ORMD-0801 for the treatment of type 1 diabetes. The company's corporate and R&D headquarters are based in Jerusalem.
For more information, the content of which is not part of this press release, please visit www.oramed.com
Danke Muddi
Oramed Announces Successful Results from Ex-US Pharmacokinetic Study of its Oral Insulin for the Treatment of Type 1 Diabetes
Company Additionally Anticipates Results from Phase 2a FDA Study for Type 2 Diabetes in January
JERUSALEM December 20, 2013-Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today successful results in a clinical trial testing the pharmacokinetic dose response of its oral insulin capsule (ORMD-0801) in type 1 diabetes patients.
Patients were treated with a different dose of oral insulin at each study visit; blood glucose and insulin levels were then monitored for the ensuing five hours. Patient responses positively correlated with administered doses, as did the duration of the effect.
"Based on these and the notable results from our previous oral insulin trials in type 1 diabetes, we continue to move forward with this indication in parallel to our advanced clinical studies in type 2 diabetes," commented CEO Nadav Kidron.
Type 1 diabetes (T1DM) is an autoimmune disease wherein the body destroys its own insulin-producing cells, leaving patients completely dependent on external insulin sources. The disease, formerly known as juvenile diabetes, currently affects both young and adult populations. According to the International Diabetes Federation, T1DM is on the rise at a rate of 3% per year and currently affects approximately 36 million people worldwide - about 10% of the global diabetes population.
About ORMD-0801 Oral Insulin and T1DM
T1DM is currently treated with two types of insulin replacement therapies: long-acting insulin (basal) to help maintain stable insulin levels during fasting periods, and pre-meal insulin (bolus) doses. Oramed proposes to introduce ORMD-0801 to replace the mealtime (bolus) insulin doses, which would significantly reduce the number of daily injections. Additionally, oral administration offers the benefit of reduced systemic exposure and may enable tighter regulation of blood sugar levels by directly affecting glucose control in the liver. For more information on ORMD-0801, the content of which is not part of this press release, please visit http://oramed.com/index.php?page=14
About Oramed Pharmaceuticals
Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (POD) technology is based on over 30 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently in Phase 2 clinical trials on patients with type 2 diabetes (T2DM) under an Investigational New Drug application with the U.S. Food and Drug Administration, and with its oral exenatide capsule (ORMD-0901; a GLP-1 analog), which has been assessed in healthy volunteers (Phase 1b) and is currently being tested in T2DM patients (Phase 2a). Oramed is also moving forward with clinical trials of ORMD-0801 for the treatment of type 1 diabetes. The company's corporate and R&D headquarters are based in Jerusalem.
For more information, the content of which is not part of this press release, please visit www.oramed.com
Danke Muddi
Antwort auf Beitrag Nr.: 46.090.916 von kwhistler am 20.12.13 15:43:04der Hammer, oder
satte 50% plus
Dat rappelt in der Kiste!
Gruß r
satte 50% plus
Dat rappelt in der Kiste!
Gruß r
Trading Spotlight
Antwort auf Beitrag Nr.: 46.089.580 von occitania am 20.12.13 12:49:50gestern gab es sie noch zum Schnapper von ca. 7 Dollar
heute muß man wesentlich tiefer in die Tasche greifen.
heute muß man wesentlich tiefer in die Tasche greifen.
Antwort auf Beitrag Nr.: 46.078.154 von reaaalist am 18.12.13 22:40:06Salut reaaalist
Deswegen habe ich mir 150 St in Stutt ins depot geschoben...
Nur So...
à bientôt
OC
Bin bis 20.45 Uhr nicht am Platz...
Deswegen habe ich mir 150 St in Stutt ins depot geschoben...
Nur So...
à bientôt
OC
Bin bis 20.45 Uhr nicht am Platz...
Antwort auf Beitrag Nr.: 46.078.036 von occitania am 18.12.13 22:23:27Aber In Israel feiert die dann nicht am 06 Januar...?
keine Ahnung
wir haben jedenfalls morgen Weihnachtsfeier!
von daher bin ich abends nicht anwesend und börsentechnisch Handlungsunfähig.
sollte Oramed überraschend auf 200 Dollar gehen, dann werde ich also auch nicht verkoofen
Gruß r
keine Ahnung
wir haben jedenfalls morgen Weihnachtsfeier!
von daher bin ich abends nicht anwesend und börsentechnisch Handlungsunfähig.
sollte Oramed überraschend auf 200 Dollar gehen, dann werde ich also auch nicht verkoofen
Gruß r
Antwort auf Beitrag Nr.: 46.077.924 von reaaalist am 18.12.13 22:10:27Salut reaaalist
Da hast du weider Recht...
Obwohl was mit Religion zu tun hast...bin da nur Kalanderisch verbunden...
Wat für Ding Biblische gesehen passiert sind...
Sollte ich am 25 12 --->PH Geburtstag mache bei Sparkäse
Null Ahnung
Aber In Israel feiert die dann nicht am 06 Januar...?
à propos: ich gehe nicht in 2014 Ohne Oramed als größter Depot Anteil
à bientôt
OC
Da hast du weider Recht...
Obwohl was mit Religion zu tun hast...bin da nur Kalanderisch verbunden...
Wat für Ding Biblische gesehen passiert sind...
Sollte ich am 25 12 --->PH Geburtstag mache bei Sparkäse
Null Ahnung
Aber In Israel feiert die dann nicht am 06 Januar...?
à propos: ich gehe nicht in 2014 Ohne Oramed als größter Depot Anteil
à bientôt
OC
Durchsuchen
Oramed Pharmaceuticals
